Table S4. Characteristics of liver cirrhosis at baseline after PS matching.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **All (n=90)** | **LLV (n=45)** | **MVR (n=45)** | ***P***  |
| Age, years | 50 (42, 54) | 49 (43, 53) | 50 (42, 56) | 0.550 |
| Male, % | 73 (81.1%) | 37 (82.2%) | 36 (80.0%) | 0.788 |
| HBeAg positive, % | 45 (50.0%) | 23 (51.1%) | 22 (48.9%) | 0.833 |
| HBV DNA, log10 IU/L | 5.29 (3.40, 6.28) | 5.43 (3.38, 6.36) | 5.10 (3.37, 6.16) | 0.597 |
| Platelet, 109/L | 102 (70, 135) | 95 (70, 139) | 112 (70, 135) | 0.553 |
| ALT, U/L | 63 (36, 92) | 65 (36, 98) | 57 (36, 92) | 0.796 |
| AST, U/L | 49 (36, 77) | 49 (39, 73) | 48 (35, 81) | 0.781 |
| Bilirubin, mmol/L | 16.9 (13.2, 25.3) | 17.4 (14.2, 25.4) | 16.1 (12.5, 24.7) | 0.429 |
| Albumin, mg/L | 43.6 (40.4, 45.8) | 43.4 (40.6, 46.4) | 43.6 (40.3, 45.5) | 0.756 |
| Treatment naïve, % | 74 (82.2%) | 39 (86.7%) | 35 (77.8%) | 0.270 |
| Treatment |  |  |  | 0.453 |
| First-line drugs, % | 72 (80.0%) | 35 (77.8%) | 37 (82.2%) |  |
| Non-first-line drugs, % | 17 (18.5%) | 10 (22.2%) | 7 (15.6%) |  |
| Non-first-line drugs combined first-line drugs, % | 1 (1.1%) | 0 (0%) | 1 (2.2%) |  |

PS matching, propensity score matching; LLV, low-level viremia; MVR, maintained virological response; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; ALT, alanine aminotransferase; AST, aspartate aminotransferase; PLT, platelets.